PROTAC CDK9 degrader-7

MedChemExpress

®

HY-149964		
2935587-90	-7	
C ₄₃ H ₅₀ Cl ₂ N ₈ O	D°	
893.81		
CDK		
Cell Cycle/D	NA Dama	age
Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month
	2935587-90 C ₄₃ H ₅₀ Cl ₂ N ₈ (893.81 CDK Cell Cycle/E Powder	2935587-90-7 C ₄₃ H ₅₀ Cl ₂ N ₈ O ₉ 893.81 CDK Cell Cycle/DNA Dama Powder -20°C 4°C In solvent -80°C

SOLVENT & SOLUBILITY

	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
		1 mM	1.1188 mL	5.5940 mL	11.1881 mL
		5 mM	0.2238 mL	1.1188 mL	2.2376 mL
		10 mM	0.1119 mL	0.5594 mL	1.1188 mL
	Please refer to the so	lubility information to select the ap	propriate solvent.		
n Vivo	1. Add each solvent o	one by one: 10% DMSO >> 90% cor g/mL (2.80 mM); Clear solution			

BIOLOGICAL ACTIV	ИТҮ		
Description	PROTAC CDK9 degrader-7 is a PROTAC targeting to CDK9 sepcifically. PROTAC CDK9 degrader-7 mediates CDK9 degradation via the proteasome ^[1] .		
In Vitro	PROTAC CDK9 degrader-7 (compound 15f) shows the great potency with an IC ₅₀ of 40 nM in the Molm-13 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[1]		
	Cell Line:	MV411 cells	
	Concentration:	0.01 μΜ, 0.05 μΜ, 0.1 μΜ, 0.5 μΜ, 1 μΜ, 5 μΜ	
	Incubation Time:	6 h	

Product Data Sheet

Children Chi

CKD9 at low concentration as 0.1μ M.	Result:	Significantly decreased the protein level of MCL2, and almostly and competely degraded
---	---------	--

REFERENCES

[1]. Tokarski RJ 2nd, et al. Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation. Eur J Med Chem. 2023 Jun 5;254:115342.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA